...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Analytical Toxicology >Development and Validation of a Novel All-Inclusive LC-MS-MS Designer Drug Method
【24h】

Development and Validation of a Novel All-Inclusive LC-MS-MS Designer Drug Method

机译：新型全包式LC-MS-MS设计师药物方法的开发与验证

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Designer drugs including synthetic cannabinoids and synthetic cathinones are an increasing problem due to the ease of access to these compounds. They present analytical challenges inasmuch as the compound structures are numerous and growing within each class. Typically each class of designer compounds is analyzed separately due to differences in chemistry, desired cut-offs or other reasons. Physicians treating high-risk patients typically order tests for all illicit substances which can span several test classes. Despite that multiple classes of designer drugs are ordered together, there has not been a comprehensive confirmatory test developed to date. Presented here is a novel comprehensive designer drug LC-MS-MS method that combines synthetic cannabinoids and synthetic cathinones, etizolam, a designer benzodiazepine and mitragynine (kratom), a natural product analgesic. This method improves laboratory throughput with a cycle time of similar to 4.5 min which affords resolution of crucial isomers, such as ethylone and butylone. Development of this method also provided an opportunity to update the list of compounds within the method. Analytes with fewer than five positive specimens in a year of testing with previous separate methods were removed as old and not current. New analytes were added based on reports from NMS Laboratories and the US Drug Enforcement Administration testing and drug seizures, which included etizolam, its major metabolite -hydroxyetizolam as well as newer synthetic cannabinoids (5-fluoro ADB metabolite 7, AB-FUBINACA metabolite 3, AB-FUBINACA metabolite 4 and MDMB-FUBINACA metabolite M1) and synthetic cathinones (N-ethyl pentylone). Finally, the impact of the new analytes and cut-off changes are discussed in context with patient results from the first 4 months of testing after implementation of the method in the lab.
机译：包括合成大麻素和合成阴茎在内的设计师药物是由于对这些化合物的易于获得而产生的越来越多的问题。它们提出了分析挑战，因为复合结构在每种阶级内众多并且生长。通常由于化学的差异，所需的截止或其他原因，每种类别的设计者化合物分别分别分析。治疗高风险患者的医生通常订购所有非法物质的测试，这些物质可以跨越几个测试类。尽管有多种类别的设计师药物被命令，但迄今为止还没有发展综合确认测试。本文提供了一种新型综合设计师药物LC-MS-MS方法，将合成大麻素和合成阴茎，Etizolam，设计师苯二氮卓和米特蛋白（Kratom），一种天然产品镇痛。该方法改善了实验室的产量，其循环时间类似于4.5分钟，这提供了重要的乙基和丁基等关键异构体的分辨率。该方法的开发还提供了更新方法内的化合物列表的机会。使用以前单独的方法的测试中少于五个阳性标本的分析物被除去旧的，而不是电流。基于NMS实验室和美国药物执法管理检测和药物癫痫发作的报道添加了新的分析物，其中包括Etizolam，其主要代谢物 - 羟基齐唑仑以及更新的合成大麻素（5氟亚替纳代谢物7，AB-Fubinaca代谢物3， AB-FUBACA代谢物4和MDMB-FUBINACA代谢物M1）和合成阴茎（N-乙基戊酮）。最后，在实验室实施方法的实施方法后，在患者的前4个月的前4个月内讨论了新的分析物和截止变化的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号